Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer.

Choi CH, Choi HJ, Lee JW, Kang ES, Cho D, Park BK, Kim YM, Kim DY, Seo H, Park M, Kim W, Choi KY, Oh T, Kang CY, Kim BG.

J Clin Med. 2020 Jan 5;9(1). pii: E147. doi: 10.3390/jcm9010147.


IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours.

Seo H, Jeon I, Kim BS, Park M, Bae EA, Song B, Koh CH, Shin KS, Kim IK, Choi K, Oh T, Min J, Min BS, Han YD, Kang SJ, Shin SJ, Chung Y, Kang CY.

Nat Commun. 2017 Jun 6;8:15776. doi: 10.1038/ncomms15776.


Virtual screening and synthesis of novel antitubercular agents through interaction-based pharmacophore and molecular docking studies.

Bhattarai D, Muddassar M, Jang JW, Hong SK, Kim EE, Oh T, Cho SN, Pae AN, Keum G.

Curr Comput Aided Drug Des. 2014;10(4):383-92.


Synthesis and in vitro evaluation of the antitubercular and antibacterial activity of novel oxazolidinones bearing octahydrocyclopenta[c]pyrrol-2-yl moieties.

Bhattarai D, Lee JH, Seo SH, Nam G, Choo H, Kang SB, Kwak JH, Oh T, Cho SN, Pae AN, Kim EE, Jeong N, Keum G.

Chem Pharm Bull (Tokyo). 2014;62(12):1214-24. Epub 2014 Oct 9.


Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim S, Yim SA, Nam J, Kang H, Kwon H, Oh CT, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SP, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Kim J, Oh S, Oh T, Nehrbass U, Han SJ, No Z, Lee J, Brodin P, Cho SN, Nam K, Kim J.

Nat Med. 2013 Sep;19(9):1157-60. doi: 10.1038/nm.3262. Epub 2013 Aug 4.


Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis.

Carroll MW, Jeon D, Mountz JM, Lee JD, Jeong YJ, Zia N, Lee M, Lee J, Via LE, Lee S, Eum SY, Lee SJ, Goldfeder LC, Cai Y, Jin B, Kim Y, Oh T, Chen RY, Dodd LE, Gu W, Dartois V, Park SK, Kim CT, Barry CE 3rd, Cho SN.

Antimicrob Agents Chemother. 2013 Aug;57(8):3903-9. doi: 10.1128/AAC.00753-13. Epub 2013 Jun 3.


Isoniazid could be used for antibiotic-loaded bone cement for musculoskeletal tuberculosis: an in vitro study.

Han CD, Oh T, Cho SN, Yang JH, Park KK.

Clin Orthop Relat Res. 2013 Jul;471(7):2400-6. doi: 10.1007/s11999-013-2899-5. Epub 2013 Mar 16.


Panosialins, inhibitors of enoyl-ACP reductase from Streptomyces sp. AN1761.

Kwon YJ, Sohn MJ, Oh T, Cho SN, Kim CJ, Kim WG.

J Microbiol Biotechnol. 2013 Feb;23(2):184-8.


Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.

Hwang JM, Oh T, Kaneko T, Upton AM, Franzblau SG, Ma Z, Cho SN, Kim P.

J Nat Prod. 2013 Mar 22;76(3):354-67. doi: 10.1021/np3007167. Epub 2013 Jan 29.


Design and synthesis of 1H-1,2,3-triazoles derived from econazole as antitubercular agents.

Kim S, Cho SN, Oh T, Kim P.

Bioorg Med Chem Lett. 2012 Nov 15;22(22):6844-7. doi: 10.1016/j.bmcl.2012.09.041. Epub 2012 Sep 23.


Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance.

Choi GE, Shin SJ, Won CJ, Min KN, Oh T, Hahn MY, Lee K, Lee SH, Daley CL, Kim S, Jeong BH, Jeon K, Koh WJ.

Am J Respir Crit Care Med. 2012 Nov 1;186(9):917-25. doi: 10.1164/rccm.201111-2005OC. Epub 2012 Aug 9.


Synthesis and in vitro antibacterial activity of novel 3-azabicyclo[3.3.0]octanyl oxazolidinones.

Bhattarai D, Lee SH, Seo SH, Nam G, Kang SB, Pae AN, Kim EE, Oh T, Cho SN, Keum G.

Chem Biol Drug Des. 2012 Sep;80(3):388-97. doi: 10.1111/j.1747-0285.2012.01404.x. Epub 2012 Jun 27.


Conversion of Mycobacterium smegmatis to a pathogenic phenotype via passage of epithelial cells during macrophage infection.

Kim SY, Sohn H, Choi GE, Cho SN, Oh T, Kim HJ, Whang J, Kim JS, Byun EH, Kim WS, Min KN, Kim JM, Shin SJ.

Med Microbiol Immunol. 2011 Aug;200(3):177-91. doi: 10.1007/s00430-011-0190-5. Epub 2011 Feb 27.


Synthesis and antitubercular activity of monocyclic nitroimidazoles: insights from econazole.

Lee SH, Kim S, Yun MH, Lee YS, Cho SN, Oh T, Kim P.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1515-8. doi: 10.1016/j.bmcl.2010.12.128. Epub 2011 Jan 5.


Identification of novel antitubercular compounds through hybrid virtual screening approach.

Muddassar M, Jang JW, Hong SK, Cho YS, Kim EE, Keum KC, Oh T, Cho SN, Pae AN.

Bioorg Med Chem. 2010 Sep 15;18(18):6914-21. doi: 10.1016/j.bmc.2010.07.010. Epub 2010 Aug 18. Erratum in: Bioorg Med Chem. 2010 Dec 1;18(23):8410. Bioorg Med Chem. 2010 Nov 1;18(21):7700. Gon, Hong Seung [correct to Hong, Seung Kon].


Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis.

Via LE, Cho SN, Hwang S, Bang H, Park SK, Kang HS, Jeon D, Min SY, Oh T, Kim Y, Kim YM, Rajan V, Wong SY, Shamputa IC, Carroll M, Goldfeder L, Lee SA, Holland SM, Eum S, Lee H, Barry CE 3rd.

J Clin Microbiol. 2010 Feb;48(2):402-11. doi: 10.1128/JCM.01476-09. Epub 2009 Dec 23.


High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.

Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M, Kim J, Genovesio A, Carralot JP, Ewann F, Kim EH, Lee SY, Kang S, Seo MJ, Park EJ, Skovierov√° H, Pham H, Riccardi G, Nam JY, Marsollier L, Kempf M, Joly-Guillou ML, Oh T, Shin WK, No Z, Nehrbass U, Brosch R, Cole ST, Brodin P.

PLoS Pathog. 2009 Oct;5(10):e1000645. doi: 10.1371/journal.ppat.1000645. Epub 2009 Oct 30.

Supplemental Content

Loading ...
Support Center